Acute Coronary Syndrome: Antiplatelets and Antithrombotics Eduardo S. Caguioa, MD., FPCP, FPCC, FACC Asst. Professor, UST Faculty of Medicine and Surgery, Dept of Medicine, Section of Cardiology Medical Director, UST Hospital Member of Advisory Board: • Astra-Zeneca • MSD • Pfizer Disclosures • Servier Receives honorarium for lectures or drug trials Have no financial interest in any drug company. Milestones in ACS Management Anti-Thrombin Rx Heparin [ Fondaparinux ] Bivalirudin LMWH Anti-Platelet Rx GP IIb/IIIa blockers Aspirin Clopidogrel Treatment Strategy Conservative Early invasive PRISM-PLUS PURSUIT ESSENCE 1994 PCI 1995 ~ 5% stents ICTUS REPLACE 2 OASIS-5 CURE 1997 1998 1999 2000 2001 ~85% stents 2002 2003 2004 Drug-eluting stents Ischemic risk Bleeding risk ACUITY SYNERGY TACTICS TIMI-18 1996 ISAR-REACT 2 Adapted from and with the courtesy of Steven Manoukian, MD 2005 2006 Evolution of ACS Therapies Low molecular weight heparin DABIGATRAN CLOPIDOGREL IIb/IIIa receptor antagonist Atorvastatin Fondaparinux Bivalirudin Aspirin Heparin Integrated strategy Early invasive management 1990 1996 1997 2000 2001 2005 2007 2008 Year Adapted from White HD et al. Lancet 2008; 372: 570–84 Proportional effects of antiplatelet therapy on Vascular events in five main high risk categories Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71–86. Absolute effects of antiplatelet therapy on vascular events in five main high risk categories Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71–86. Clopidogrel in NSTE ACS: CURE 12,563 Pts, GP IIb/IIIa & early invasive approach discouraged 0.14 Placebo (11.4%) 0.12 CV Death, MI, Stroke 0.10 Clopidogrel (9.3%) 0.08 0.06 RR 0.80, p<0.001 0.04 0.02 0.0 0 3 6 Months of follow-up CURE. NEJM 2001;345:494-502 9 12 Cumulative Hazard Rate CURE: Very Early Efficacy of Clopidogrel in NSTE ACS CV Death, MI, Stroke, Severe Ischemia Within First 24 Hours 0.025 34% 0.020 Relative Risk Reduction Placebo + Aspirin (n=6303) 0.015 0.010 P=.003 Clopidogrel + Aspirin (n=6259) 0.005 0.0 0 2 4 6 8 10 12 14 16 18 Hours After Randomization Yusuf S et al. Circulation 2003;107:966-972 20 22 24 Clopidogrel in STEMI Double-blind, randomized, placebo-controlled trial in 3491 patients, age 18-75 yrs with STEMI < 12 hours Fibrinolytic, ASA, Heparin randomize Clopidogrel 300 mg + 75 mg qd Placebo Study Drug Coronary Angiogram (2-8 days) Open-label clopidogrel per MD in both groups 30-day clinical follow-up Primary endpoint: Occluded artery (TIMI Flow Grade 0/1) or D/MI by time of angio 15 10 Clopidogrel Odds Ratio 0.80 (95% CI 0.65-0.97) P=0.026 0 5 20% 10 15.0 Placebo 5 20 36% P<0.0001 21.7 CV Death, MI, or Urg Revasc (%) Occluded Artery or Death/MI (%) 25 in STEMI 15 Clopidogrel 0 Clopidogrel Placebo 0 5 10 Sabatine MS et al. NEJM 2005; 352: 1179 15 days 20 25 30 PCI-CLARITY Design 3491 Patients Randomized into CLARITY-TIMI 28 1752 assigned clopidogrel 300 mg 75 mg/d (CLOPIDOGREL PRETREATMENT) Open-label clopidogrel w/ loading dose recommended 1739 assigned placebo (NO PRETREATMENT) A n g i o g r a p h y 933 underwent PCI during index hosp. 930 underwent PCI during index hosp. 30-day clinical follow-up Odds Ratio 0.54 No Pretreatment – 6.2% (95% CI 0.35-0.85) 6 P=0.008 4 46% 2 Clopidogrel – 3.6% Pretreatment Sabatine MS et al. JAMA 2005;294:1224-32 0 Percentage with outcome (%) 8 CV Death, MI, or Stroke following PCI 0 10 Days post PCI 20 30 Meta-Analysis of Clopidogrel Pretreatment MI before PCI (%) Clopidogrel Pretreatment No Pretreatment PCI-CURE 3.6 5.1 CREDO n/a n/a PCI-CLARITY 4.0 6.1 Overall 3.7 5.5 Trial Favors Pretreatment Favors No Pretreatment OR 0.67 P=0.005 CV Death or MI after PCI (%) Trial Clopidogrel Pretreatment No 0.25 Pretreatment PCI-CURE 2.9 4.4 CREDO 6.0 7.1 PCI-CLARITY 3.3 5.4 Overall 3.9 5.5 0.5 1.0 OR (95% CI) 2.0 OR 0.71 P=0.004 Sabatine MS et al. JAMA 2005;294:1224-32 0.25 0.5 1.0 OR (95% CI) 2.0 20 Variable and Unpredictable Response to Clopidogrel Patients (%) 20 24 hrs after 300 mg Clopidogrel N = 96, Elective PCI “Resistance” = 31% 10 ≤ -30 (-20,-10) (-30,-20) (-10,0) (0,10) (20,30) (10,20) (40,50) (30,40) >60 (50,60) Platelet aggregation before and after Clopidogrel (%) “Resistance” = ≤ 10% platelet aggregation 2015.01 Gurbel PA et al. Circulation 2003; 107: 2908-2913 21 Clopidogrel Response Variability and Increased Risk of Ischemic Events Primary PCI for STEMI (N = 60) 5 µM ADP induced plt agg 120 Clop resist 100 40 40 Q1 80 Q2 60 Q3 40 Q4 20 P = 0.007 30 Percent Baseline (%) Death/ACS/CVA by 6 m 20 10 6.7 Quartiles of response 0 1 2 3 4 Days 5 6 0 Q1 Q2 0 0 Q3 Q4 Matetzky S, et al. Circulation. 2004;109:3171-3175. Wiviott SD, Antman EM. Circulation. 2004 109:3064-3067. 3116.01 Evolution of ACS Therapies Low molecular weight heparin CLOPIDOGREL Atorvastatin PRASUGREL IIb/IIIa receptor antagonist Fondaparinux Bivalirudin Aspirin Heparin Integrated strategy Early invasive management 1990 1996 1997 2000 2001 2005 2007 2008 Year Adapted from White HD et al. Lancet 2008; 372: 570–84 More Efficient and Less Variable Activation of Prasugrel Compared to Clopidogrel Prasugrel Clopidogrel hCE1 85% Inactive Metabolite Liver CYP1A2, 2B6, 2C19 Gut hCE2 Intermediate Intermediate Gut Liver CYP3A, 2B6, 2C9, 2C19 and CYP3A, 2B6, 2C9, 2C19 Liver Active Metabolite CYP2C19 variants and inhibitors affect the PK and PD of clopidogrel Active Metabolite Prasugrel has no clinically relevant interactions with CYP2C19 variants or inhibitors Higher Active Metabolite Concentrations of Prasugrel After Loading Dose Active Metabolite Concentration (ng/mL) 600 Cmax and Tmax influence onset of platelet inhibition • Relevant for loading dose but not maintenance dose AUC influences extent of platelet inhibition • Relevant for loading and maintenance dose 500 400 Prasugrel 60 mg LD 300 Clopidogrel 600 mg LD Clopidogrel 300 mg LD 100 0 0 2 Time (Hrs) 4 6 8 Prasugrel 60 mg LD with 10 mg MD Demonstrates Superior Response Compared to Clopidogrel 60 52% (%) Non Responders 50 Loading dose 40 Maintenance dose 45% 36% 30 21% 20 10 3% 0 Pras 40 mg 3% Pras Clop 60 mg 300 mg Day 1 (4 hr) Pras 5 mg 0% 0% Pras Pras Pras 7.5 mg 10 mg 15 mg Day 28 (0 hr) Clop 75 mg Jernberg et al., Eur Heart J 2006; 27:1166-1173 TRITON-TIMI 38 Study Design ACS (STEMI or UA/NSTEMI) & Planned PCI ASA N = 13,608 Double-blind CLOPIDOGREL 300 mg LD/ 75 mg MD PRASUGREL 60 mg LD/ 10 mg MD Median duration of therapy - 12 months 1o endpoint: 2o endpoints: CV death, MI, stroke CV death, MI, stroke, rehosp-Rec Isch CV death, MI, UTVR Stent thrombosis (ARC definite/prob.) Safety endpoints: TIMI major bleeds, life-threatening bleeds Key substudies: Pharmacokinetic, genomic Balance of Efficacy and Safety: All ACS 15 Clopidogrel 12.1% Endpoint (%) CV death / MI / stroke 10 9.9% Prasugrel 5 TIMI major Non-CABG bleeds Prasugrel Clopidogrel 2.4% 1.8% 0 0 30 60 90 180 270 360 450 138 events HR 0.81 (0.73 - 0.90) P = 0.0004 NNT = 46 35 events HR 1.32 (1.03 - 1.68) P = 0.03 NNH = 167 Days Wiviott SD et al. NEJM 2007; 357: 2001-2015 Antiplatelet Therapy in ACS ASA 100 ASA + Clopidogrel ASA + Prasugrel Ischemic events - 22% Reduction in Ischemic Events - 20% - 19% + 60% + 38% 0 Placebo APTC Single Antiplatelet Rx CURE Dual Antiplatelet Rx Increase in + 32% Major Bleeds TRITON-TIMI 38 Higher IPA Wiviott SD et al. NEJM 2007; 357: 2001-2015 Net Clinical Benefit in Subgroups: Death / MI / CVA / Major Bleed Post-Hoc Analysis Prior TIA / stroke Risk (%) + 54 Yes No Pint = 0.006 ≥ 75 yrs -16 -1 Age < 75 yrs Weight Pint = 0.18 < 60 kg +3 ≥ 60 kg Pint = 0.36 -14 -13 OVERALL 0.5 -16 Favors Prasugrel 1 HR Favors Clopidogrel 2 Wiviott SD et al. NEJM 2007; 357: 2001-2015 Balance of Efficacy and Safety in Patients < 75 Yrs, ≥ 60 kg, and without Prior TIA/Stroke 16 CV death, NF MI, or NF stroke 14 Clopidogrel 11.0% Endpoint (%) 12 10 Hazard Ratio, 0.75 (95% CI, 0.66 - 0.84) P < 0.001 8 Prasugrel 8.3% 6 4 TIMI major bleeding Hazard Ratio, 1.240 (95% CI, 0.91 - 1.69) P = 0.17 2 Prasugrel 2.0% Clopidogrel 1.50% 0 0 30 90 180 270 360 450 Days Modified from Wiviott SD et al. NEJM 2007; 357: 2001-2015 Kaplan-Meier estimates of the incidence of the primary composite endpoint and of non-CABG related TIMI Major bleeding for All ACS patients with diabetes. All ACS Patients with Diabetes KM Estimates of Event Rate (%) 20 Clopidogrel 17.0% CV Death, NF MI , or NF Stroke 15 Hazard Ratio, 0.705 (95% CI, 0.58-0.85) p<0.001 10 Prasugrel 12.2% Prasugrel 2.6% Clopidogrel 2.5% 5 TIMI Major Bleeding 0 0 30 90 180 270 360 Days From Randomization or First Dose 450 Hazard Ratio, 1.06 (95% CI, 0.66-1.69) p=0.81 Therapeutic Considerations 16% 4% MD 10 mg Significant Net Clinical Benefit with Prasugrel 80% Wiviott SD et al. NEJM 2007; 357: 2001-2015 Aspirin Clopidogrel Prasugrel ? August 30, 2009 TICAGRELOR: First and Only Approved CPTP TICAGRELOR, a new chemical class, is a cyclo-pentyl-triazolo-pyrimidine (CPTP) Ticagrelor is direct acting (not a prodrug and does not require metabolic activation) It binds directly to P2Y12 receptors and reversibly interacts with the receptor, to prevent platelet activation and aggregation Thienopyridines bind covalently to P2Y12 ADP binding site for the life of the platelet Husted S, et al. Eur Heart J. 2006;27:1038–1047. Gurbel PA, et al. Expert Opin Drug Metab Toxicol. 2009;5(8):989–1004. Van Giezen JJ, et al. J Thromb Haemost. 2009;7:1556-1565. ADP binding site Ticagrelor P2Y12 receptor on platelet Inhibition of Platelet Aggregation: Onset Inhibition of Platelet Aggregation 100 * Ticagrelor (n=54) * * * * 80 Clopidogrel (n=50) 60 * 40 Placebo (n=12) 20 0 0 2 Loading Dose 4 6 8 10 12 14 16 18 20 22 24 Time (Hours) Ticagrelor 180-mg loading dose in Stable CAD patients Clopidogrel 600-mg loading dose in Stable CAD patients *P<0.0001Ticgrelor vs Clopidogrel Adapted from Gurbel PA, et al. Circulation. 2009;120:2577–2585. PLATO: Study Design 18,624 patients with ACS (UA, NSTEMI, or STEMI*) randomized within 24 hours of symptom onset Initial treatment approaches • Medically managed (n=5,216 — 28.0%) • Invasively managed (n=13,408 — 72.0%) Patients could be taking clopidogrel at time of randomization Ticagrelor (n=9,333) Clopidogrel (n=9,293) 300-mg loading dose† 75 mg qd + ASA Maintenance dose 180-mg loading dose 90 mg bid + ASA Maintenance dose 6–12 months of double-blind treatment Primary efficacy endpoint: Primary safety endpoint: Composite of CV death, MI (excluding silent MI), or stroke Total PLATO major bleeding‡ *STEMI patients scheduled for primary PCI were randomized; however, they may not have received PCI. †A loading dose of 300-mg clopidogrel was permitted in patients not previously treated with clopidogrel, with an additional 300 mg allowed at the discretion of the investigator. ‡The PLATO study expanded the definition of major bleeding to be more inclusive compared with previous studies in ACS patients. The primary safety endpoint was the first occurrence of any major bleeding event. 1. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. 2. James S, et al. Am Heart J. 2009;157:599–605. PLATO Main: Inclusion Criteria Hospitalisation for STEMI or NSTEMI/UA ACS, with onset during previous 24 hours With STEMI, the following 2 inclusion criteria were required • Persistent ST elevation of at least 0.1 mV in ≥2 contiguous leads or new LBBB • Primary PCI planned With NSTEMI, at least 2 of the following 3 were required • ST changes on ECG indicating ischaemia • Positive biomarker indicating myocardial necrosis • One of the following risk indicators ≥60 years of age Previous MI or CABG CAD with ≥50% stenosis in ≥2 vessels Previous ischaemic stroke, TIA, carotid stenosis (≥50%), or cerebral revascularisation Diabetes mellitus Peripheral artery disease Chronic renal dysfunction (creatinine clearance <60 mL/min) James S, et al. Am Heart J. 2009;157:599–605. PLATO: Baseline Characteristics TICAGRELOR (n=9,333) Clopidogrel (n=9,291) 62.0 62.0 Age ≥75 years, n (%) 1,396 (15.0) 1,482 (16.0) Women, n (%) 2,655 (28.4) 2,633 (28.3) Habitual smoker 3,360 (36.0) 3,318 (35.7) Hypertension 6,139 (65.8) 6,044 (65.1) Dyslipidemia 4,347 (46.6) 4,342 (46.7) Diabetes mellitus 2,326 (24.9) 2,336 (25.1) MI 1,900 (20.4) 1,924 (20.7) PCI 1,272 (13.6) 1,220 (13.1) 532 (5.7) 574 (6.2) ST-segment elevation, persistent 3,497 (37.5) 3,511 (37.8) ST-depression 4,730 (50.7) 4,756 (51.2) T-wave inversion 2,970 (31.8) 2,975 (32.0) 7,965 (85.3) 7,999 (86.0) Characteristic Median age, years CV risk factors, n (%) History, n (%) CABG ECG at study entry, n (%) Troponin-I positive, n (%) Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. Cumulative Incidence (%) PLATO: Primary Efficacy Endpoint (Composite of CV Death, MI, or Stroke) 13 12 11 10 9 8 7 6 5 4 3 2 1 0 0–30 Days 0–12 Months 11.7 Clopidogrel 9.8 TICAGRELOR Clopidogrel 5.4 4.8 TICAGRELOR ARR=0.6% ARR=1.9% RRR=12% RRR=16% P=0.045 NNT=54* HR: 0.88 (95% CI, 0.77−1.00) P<0.001 HR: 0.84 (95% CI, 0.77–0.92) 0 2 4 6 8 10 12 Months After Randomization No. at risk TICAGRELOR 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Clopidogrel 9,291 8,521 8,362 8,124 6,650 5,096 4,047 Both groups included aspirin. *NNT at one year. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. PLATO: Predefined Testing of Primary and Major Secondary Efficacy Endpoints TICAGRELOR (n=9,333) Clopidogrel (n=9,291) HR for TICAGRELOR (95% CI) P Value** 864 (9.8) 1,014 (11.7) 0.84 (0.77–0.92) <0.001 901 (10.2) 1,065 (12.3) 0.84 (0.77–0.92) <0.001 1,290 (14.6) 1,456 (16.7) 0.88 (0.81–0.95) <0.001 MI† 504 (5.8) 593 (6.9) 0.84 (0.75–0.95) 0.005 Death from vascular causes 353 (4.0) 442 (5.1) 0.79 (0.69–0.91) 0.001 Stroke 125 (1.5) 106 (1.3) 1.17 (0.91–1.52) 0.22 Death from any cause 399 (4.5) 506 (5.9) 0.78 (0.69–0.89) <0.001‡ All Patients* Primary endpoint, n (%/year) Death from vascular cause + MI† + stroke Secondary endpoints, n (%/yr) Death from any cause + MI† + stroke Death from vascular causes + MI† + stroke + severe recurrent ischemia + recurrent ischemia + TIA + arterial thrombus Nominal Significance * Patients could have had more than one type of endpoint. Death from CV causes and fatal bleeding, as only traumatic fatal bleeds were excluded from the CV death category. ** By Cox regression analysis using treatment as factor; †Excluding silent MI; ‡Death from any cause was tested after stroke, which was non-significant, so the results should be considered nominally significant. Both groups included aspirin. The percentages presented are Kaplan-Meier estimates of the rate of the endpoint at 12 months. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. PLATO: Secondary Efficacy Endpoints Cardiovascular Death Myocardial Infarction Clopidogrel 6 5.8 TICAGRELOR 5 4 3 ARR=1.1% 2 RRR=16% Calculated NNT=91 1 7 Cumulative Incidence (%) Cumulative Incidence (%) 7 6.9 6 Clopidogrel 4.0 4 TICAGRELOR 3 ARR=1.1% 2 RRR=21% NNT=91 1 P=0.005 P=0.001 HR: 0.84 (95% CI, 0.75–0.95) 2 4 6 8 10 Months After Randomisation HR: 0.79 (95% CI, 0.69–0.91) 0 0 0 5.1 5 12 0 2 4 6 8 Months After Randomisation Rate of stroke for TICAGRELOR was not different from clopidogrel (1.3% vs 1.1% ), P=0.225. Both groups included aspirin. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. Supplement. BRILIQUE: Summary of Product Characteristics, 2010. 10 12 PLATO: Primary Safety Endpoint PLATO-defined Total Major Bleeding (%) 15 TICAGRELOR Clopidogrel 10 11.6% 11.2% 5 P=0.43 HR: 1.04 (95% CI, 0.95–1.13) 0 0 60 120 180 240 300 360 Days From First Dose No. at risk TICAGRELOR 9,235 7,246 6,826 6,545 5,129 3,783 3,433 Clopidogrel 9,186 7,305 6,930 6,670 5,209 3,841 3,479 Both groups included aspirin. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. P=NS PLATO: Bleeding 18 BRILINTA (n=9,235) P = 0.008 K-M Estimated Rate (% Per Year) 16.1 16 Clopidogrel (n=9,186) 14.6 14 NS 12 11.6 11.2 10 NS 8 NS 5.8 6 7.4 5.8 4.5 4 2 NS 0.3 7.9 P = 0.03 3.8 0.3 0 Major Bleeding Life-threatening/ Fatal Bleeding Fatal Bleeding All values presented by PLATO criteria. Both groups included aspirin. Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. Major and Minor Bleeding Non-CABG-Major Bleeding CABG-Major Bleeding PLATO: Dyspnea Dyspnoea in the PLATO trial Ticagrelor Clopidogrel P Value Incidence of dyspnea adverse events (%) 13.8 7.8 <0.001 Patients who discontinued treatment due to dyspnoea (%) 0.9 0.1 <0.001 Ticagrelor-associated dyspnea was mostly mild to moderate in severity and did not reduce efficacy Most events were reported as single episode occurring early after starting treatment Not associated with new or worsening heart or lung disease In 2.2% of patients, investigators considered dyspnoea causally related to treatment with Ticagrelor Label precautions and warnings: use with caution in patients with history of asthma and COPD Ticagrelor: Summary of Product Characteristics, 2010.; Wallentin L, et al. N Engl J Med. 2009;361:1045–1057. Storey R, et al. J Am Coll Cardio. 2010;55(Suppl 1):A108.E1007. PLATO: Bradycardia-related Events Ticagrelor (n=9,235) Clopidogrel (n=9,186) P Value Pacemaker insertion 82 (0.9) 79 (0.9) 0.87 Syncope 100 (1.1) 76 (0.8) 0.08 Bradycardia 409 (4.4) 372 (4.0) 0.21 Heart Block 67 (0.7) 66 (0.7) 1.00 All Patients Bradycardia-related event, n (%) • Ventricular pauses ≥3 seconds occurred in 5.8% of ticagrelor-treated patients vs 3.6% of clopidogrel-treated patients in the acute phase, and 2.1% and 1.7% after 1 month, respectively • There were no differences in adverse clinical consequences (ie, pacemaker insertion, syncope, bradycardia, and heart block) • Label precautions and warnings: Ticagrelor should be used with caution in patients at risk of bradycardic events Wallentin L, et al. N Engl J Med. 2009;361:1045–1057.; Ticagrelor: Summary of Product Characteristics, 2010. PLATO: Laboratory Parameters Ticagrelor (n=9,235) Clopidogrel (n=9,186) P Value At 1 month 10 ± 22 8 ± 21 <0.001 At 12 months 11 ± 22 9 ± 22 <0.001 1 month after end of treatment 10 ± 22 10 ± 22 0.59 At 1 month 14 ± 46 7 ± 44 <0.001 At 12 months 15 ± 52 7 ± 31 <0.001 1 month after end of treatment 7 ± 43 8 ± 48 0.56 All Patients Mean % increase (± SD) in serum creatinine from baseline Mean % increase (± SD) in serum uric acid from baseline • Creatinine levels may increase during treatment with ticagrelor; renal function should be checked after 1 month and thereafter according to medical practice • Label precautions and warnings: as a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged Wallentin L, et al. N Engl J Med. 2009;361:1045–1057.; Ticagrelor: Summary of Product Characteristics, 2010. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Christopher P. Cannon, Robert A. Harrington, Stefan James, et al. for the PLATelet inhibition and patient Outcomes (PLATO) investigators Presented at ESC 2009 as an oral presentation Subsequently published in Lancet, January 2010 A pre-specified objective of PLATO was to compare outcomes of Ticagrelol versus clopidogrel in patients with planned invasive strategy at randomization For all patients, the intention for early invasive management had to be indicated by the investigator before patients were randomized Cannon CP, et al. Lancet. 2010;375:283−293. PLATO Primary Endpoint: Initial Invasive vs Initial NonInvasive Management Initial Non-Invasive 28% of patients in PLATO 10.7% Clopidogrel 9% Ticagrelor P<0.0025 HR: 0.84 (95% CI, 0.75–0.94) K-M Estimated Rate Primary Composite of CV Death/MI/Stroke (%) K-M Estimated Rate Primary Composite of CV Death/MI/Stroke (%) Initial Invasive 72% of patients in PLATO 16 14.3% 14 Clopidogrel 12% 12 10 Ticagrelor 8 6 4 P<0.045 2 HR: 0.85 (95% CI, 0.73–1.00) 0 0 Days After Randomisation 60 120 180 240 300 360 Days After Randomisation No. at risk Ticagrelor 6,732 6,236 6,134 5,972 4,889 3,735 3,048 Ticagrelor 2,601 2,392 2,326 2,247 1,854 1,426 1,099 Clopidogrel 6,676 6,129 6,034 5,881 4,815 3,680 2,965 Clopidogrel 2,615 2,392 2,328 2,243 1,835 1,416 1,109 James S, et al. ESC 2010; Poster #1353.; Cannon C, et al. Lancet. 2010;375:283–293. Clinical Implications In ACS patients with planned invasive management at randomisation in PLATO, compared with clopidogrel, ticagrelor significantly reduced the incidence of • CV death/MI/stroke (primary efficacy endpoint) Ticagrelol: 9.0% vs clopidogrel: 10.7% • CV death Ticagrelol: 3.4% vs clopidogrel: 4.3% Consistent with the overall study, ticaggrelor had an increase in dyspnea in this patient population compared to clopidogrel In PLATO, in ACS patients with a planned invasive management strategy, Ticagrelol was shown to be more effective than clopidogrel for the prevention of CV and total death without any significant increase in major bleeding* Invasive study was consistent with the overall results from PLATO * No overall increase in major bleeding in this sub-study, however there was an increase in the PLATO main non-CABG bleeding (Ticagrelor: 4.5% vs. clopidogrel 3.8%); and major and minor bleeding (Ticagrelor16.1% vs. clopidogrel 14.6%). European Association for Percutaneous Cardiovascular Intervention, et al. Eur Heart J. 2010;31:2501–2555. Canadian Cardiovascular Society Anti Platelet Guidelines published online at http://www.ccs.ca. Accessed February 12, 2011. Adapted form Cannon CP, et al. Lancet. 2010;375:283−293. TICAGRELOR Indication By Diagnosis By Treatment UA/NSTEMI STEMI Medical management PCI CABG Ticagrelor, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non–ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) If clinically indicated, Ticagrelor should be used with caution in the following patient groups: Patients with concomitant administration of medicinal products that may increase the risk of bleeding (eg, non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of ticagrelor dosing Ticagrelor: Summary of Product Characteristics, 2010. Aspirin Clopidogrel Prasugrel Ticagrelor ? New Anticoagulants in AF and ACS Perspective: 1. The availability, of new treatment alternatives for stroke prevention in patients with nonvalvular atrial fibrillation is a great step forward to further improve outcomes and quality of life. 2. Compared with warfarin, these new alternatives have important advantages, with their lower risk of intracranial bleeding, no clear interactions with food, fewer interactions with medications, and no need for frequent laboratory monitoring and dose adjustments. 3. Dabigatran etexilate is a synthetic low molecular weight peptidomimetic that binds directly and reversibly to the catalytic site of thrombin. 4. Rivaroxaban, apixaban, and endoxaban are selective direct factor Xa inhibitors. 5. Based on the currently available results from the individual trials, it is clear that both the oral direct thrombin inhibitor dabigatran etexilate and the oral factor Xa inhibitors apixaban and rivaroxaban are attractive alternatives to warfarin or aspirin in patients with nonvalvular atrial fibrillation and an increased risk of stroke. New Anticoagulants in AF and ACS Perspective: 6. Apixaban 5 mg (with dose reduction to 2.5 mg in specific cases) BID is currently the best documented alternative to both warfarin and aspirin for stroke prevention in a broad population with atrial fibrillation and increased risk of stroke, based on two independent large-scale trials. Apixaban is awaiting Food and Drug Administration approval in the United States for atrial fibrillation. 7. Patients already on long-term vitamin K antagonist (VKA) treatment, with wellcontrolled international normalized ratio and handling VKA treatment and laboratory monitoring without problems, derive uncertain overall advantages from switching to the new oral anticoagulants, and the arguments for changing treatment in such patients appear weak. 8. There is also a need for more information on how to manage patients with bleeding because there are no specific antidotes for any of the new agents. 9. The cost of the drug at the patient level might be an obstacle to their use, although the cost-effectiveness at a societal level might be tolerable in comparison with other recently accepted novel treatments. 10. Additional trials are indicated to determine the utility of these agents in combination with antiplatelet treatments after myocardial infarction and percutaneous coronary intervention. Thank you for your attention!